Gut health · 11 minute read
Do digestive enzymes for IBS work? Naturopath Adrian Stone unpacks the new FODMAP enzyme research and digestive enzymes for bloating.
Adrian Stone, nutritionist and naturopath
By Adrian Stone, BHSc (Nutritional Medicine), BHSc (Naturopathy), Living Holistic Health — new research on digestive enzymes for IBS is getting plenty of attention. Here’s what the studies actually show, where they fall short, and why knowing your trigger still comes first.
If you live with irritable bowel syndrome (IBS), you’ve probably done the low FODMAP diet, or at least heard of it. It works for a lot of people. However, it is also hard work, restrictive, and tricky to keep up at a dinner party or a family barbecue.
So when a headline says IBS symptoms improved with a FODMAP-targeting enzyme combination, people take notice. I did too. Below, I’ll walk through the new research, explain how these enzymes work, and give you my honest read on where they fit.
For some people, possibly — but mostly when the enzyme matches the specific FODMAP that sets them off. The newest studies on combination enzyme blends are encouraging. Even so, the strongest of them had no placebo group, and most were funded by the companies selling the enzymes. In other words, it’s promising early evidence rather than a settled answer.
That nuance matters. IBS isn’t one condition with one cause. For example, one person reacts to garlic and onion, while another reacts to lentils or milk. An enzyme can only help with the FODMAP it actually breaks down. As a result, “do digestive enzymes for IBS work?” really depends on which enzyme, for which person, and for which food.
In a 2026 real-world study, most people who used a FODMAP-targeting enzyme blend for four weeks reported less bloating, wind and abdominal pain. However, the design means we can’t yet tell how much of that came from the enzymes themselves.
According to PubMed, Kaye and colleagues (2026) surveyed people who had bought a FODMAP-targeting enzyme blend online, before and after four weeks of use. Here’s what they reported:
Quality of life, mental wellbeing and food avoidance also improved on average.
Those numbers look impressive. Still, there are three things worth knowing. First, there was no placebo group, and IBS is famous for a strong placebo response. Second, participants were people who had already chosen to buy the product, so they were hopeful from the start. Third, several authors work for the company that makes the blend.
None of that makes the findings wrong. It simply means this is a first signal, not proof. Fortunately, a placebo-controlled trial of an enzyme blend in people with bloating is already listed on ClinicalTrials.gov and under way (NCT07591584). That’s the study I’m waiting for.
Meanwhile, a separate 2026 randomised, double-blind trial tested a single enzyme, fructanase, in 30 healthy adults given a large dose of inulin (a fructan). Over the first eight hours, overall symptom scores weren’t significantly different from placebo. Over the following 8–24 hours, though, bloating, pain and wind were lower with the enzyme. Notably, these were healthy volunteers, not people with IBS.
They break down specific FODMAP sugars in the small intestine, before those sugars reach the bacteria in your large bowel. Less undigested FODMAP reaching the colon should mean less fermentation, less gas and less stretching of a sensitive gut.
Here’s the mechanism in plain terms. FODMAPs are short-chain carbohydrates that the small intestine absorbs poorly. Instead, they travel to the large bowel, where bacteria ferment them and produce gas. They also draw water into the bowel. For most people, that causes few problems. In IBS, however, the gut is often more sensitive to stretch, so the same amount of gas hurts more.
I often tell clients that your gut is not like Las Vegas. What happens in the small intestine doesn’t stay there. Whatever escapes digestion moves on and becomes the large bowel’s problem. Enzymes aim to finish the job earlier, so less arrives downstream.
Each FODMAP needs a different enzyme, which is why combination blends exist. These are the main ones studied:
Alpha-galactosidase breaks down galacto-oligosaccharides (GOS), found in lentils, chickpeas and beans. Humans don’t make this enzyme, so GOS always reaches the large bowel. It’s also the best-studied enzyme in IBS, which I’ll come back to below.
Fructans are found in wheat, onion and garlic, and they’re among the most common IBS triggers. We have no enzyme of our own to digest them either. Fructanase is designed to break them down, and it’s the enzyme tested in the 2026 inulin trial above. Invertase works on related sugars and appears in some blends.
Lactase splits lactose, the sugar in milk. Many adults produce less of it as they age. Of all the enzymes here, lactase is the most familiar. Even so, it only helps if lactose is actually one of your triggers.
Xylose isomerase converts fructose into glucose, which is absorbed more easily. In a double-blind trial of 65 people with breath-test-confirmed fructose malabsorption, it more than halved breath hydrogen after a fructose drink. It also reduced abdominal pain and nausea, although the change in bloating didn’t quite reach significance.
The evidence on digestive enzymes for bloating is mixed. Matched to the right trigger, they’ve reduced bloating in some controlled trials. Used broadly, without knowing the trigger, the results have been far less convincing.
Alpha-galactosidase shows this well. In a Monash University trial from Melbourne, people with IBS ate GOS-rich foods with either the enzyme or a placebo. Among the 21 people who were clearly GOS-sensitive, the enzyme markedly reduced overall symptoms and bloating.
By contrast, two other trials found little benefit. A small Swedish crossover study saw no difference from placebo after high-oligosaccharide meals. Similarly, a 12-week Finnish trial in 125 people with IBS found only a trend towards improvement. In that trial, more people stopped taking the enzyme because of gut symptoms than stopped the placebo.
The pattern, then, is clear enough. Enzymes seem to do best when the person, the FODMAP and the enzyme all line up. That’s precisely why digestive enzymes for bloating aren’t a one-size-fits-all answer.
No. The low FODMAP diet has a much deeper evidence base. Enzymes are better thought of as a possible tool for flexibility, once you know your triggers, rather than a way to avoid finding them.
A 2026 meta-analysis of 10 randomised trials (939 people) found the low FODMAP diet gave fairly consistent short-term benefit, with responder rates between 34% and 78%. Interestingly, a Mediterranean-style low FODMAP approach looked promising for the longer term.
Also, remember the low FODMAP diet was never meant to be forever. It has three stages: reduce, reintroduce, then personalise. The reintroduction stage is where you discover your own triggers. Without it, you can end up avoiding far more food than you need to.
Potentially, yes. Many FODMAPs also feed beneficial gut bacteria. Breaking them down early may reduce some of the good things those bacteria make.
In a 2023 laboratory study using a gut simulator and stool from people with IBS, pre-digesting FODMAPs with an enzyme mix reduced gas and supported microbial diversity. However, it also lowered short-chain fatty acid production. Short-chain fatty acids, such as butyrate, help nourish the cells lining the bowel. This was a lab model, funded by industry, so it isn’t the final word. Still, it’s a reminder that gas isn’t the only thing fermentation produces.
This is the same trade-off we see with long-term FODMAP restriction. In short, the aim is to keep as much diverse, fibre-rich food in your diet as your gut comfortably allows. Our gut health page covers the bigger picture.
Because an enzyme only works on the FODMAP it targets, guessing at triggers tends to waste time and money. Identifying which FODMAPs bother you, and how much of each you tolerate, is the step that makes everything else make sense.
I say this a lot: if you don’t test, you’re only guessing. Every one of the more convincing trials above was in people with a confirmed, specific sensitivity. That’s not a coincidence.
In clinic, where a test will change the plan, I use comprehensive gut microbiome testing rather than a single breath test. A breath test looks at one sugar at a time. A stool-based microbiome test goes deeper: it shows which bacteria are doing the fermenting, along with markers of digestion and gut inflammation. Combined with a structured FODMAP reintroduction, that can help explain why certain foods cause trouble, not just which ones.
From there, any digestive support is decided case by case. Sometimes strengthening digestion is part of the plan; often the bigger levers are diet, the microbiome and the nervous system. Either way, it’s one piece of a wider plan rather than a standalone answer.
It’s also worth remembering that IBS symptoms overlap with other conditions. Coeliac disease, inflammatory bowel disease and others need ruling out by your doctor first. If you notice bleeding, unexplained weight loss, a change in bowel habit after 50, or symptoms that wake you at night, see your GP promptly.
We don’t diagnose or treat irritable bowel syndrome; that stays with your doctor. Our part is the nutritional, herbal and lifestyle work that sits alongside their care.
General information only, not individual medical advice. Always discuss supplements and herbal medicines with your treating practitioner.
The honest summary? Digestive enzymes for IBS are interesting, and the research is moving quickly. Right now, though, the best evidence supports a targeted enzyme for a known trigger, not a blanket blend in place of understanding your gut.
The path to progress is never linear, and IBS is a good example. If you’d like help mapping your triggers, talk to a naturopath in Geelong or Drysdale. You can book an appointment with me here, or read more about how we approach irritable bowel.
Some people with IBS report less bloating, wind and pain with FODMAP-targeting enzymes. The best controlled evidence is for an enzyme matched to a confirmed trigger, such as alpha-galactosidase for GOS. Results for broad combination blends are encouraging but come mainly from uncontrolled, industry-funded studies.
Fructanase is the enzyme designed to break down fructans from wheat, onion and garlic. A 2026 randomised trial found it reduced bloating, pain and wind 8–24 hours after a large inulin dose in healthy adults. Trials in people with IBS are still needed.
In the trials, it was taken with meals containing GOS-rich foods such as legumes. It only acts on GOS, so it has no effect on other FODMAPs. Talk with your practitioner about whether it suits your situation before using it.
In the 2026 real-world study, about 73% of people with constipation-predominant IBS reported improvement. However, that group was small and there was no placebo comparison, so this finding needs confirming in a controlled trial.
Very little. Most trials ran from a single meal to 12 weeks. In one 12-week trial, more people stopped the enzyme than the placebo because of gut symptoms. Lab research also suggests pre-digesting FODMAPs may reduce helpful short-chain fatty acids.
The low FODMAP diet, especially its reintroduction stage, is still the best-studied way to identify your personal triggers. Enzymes may later add flexibility for a known trigger. Ideally, work through the diet with a qualified practitioner rather than restricting long term.
Kaye AJ, Meyers SR, Hachuel D, et al. FODMAP-targeting digestive enzyme blend for management of gastrointestinal symptoms: a “real-world” pre-post intervention cohort study. Gastro Hep Advances. 2026. doi:10.1016/j.gastha.2026.100898 (several authors employed by the manufacturer).
Mah E, McKenna CF, Blonquist TM, et al. Oral fructanase administration reduces gastrointestinal symptom severity after acute inulin challenge in healthy adults. The Journal of Nutrition. 2026. doi:10.1016/j.tjnut.2026.101782
ClinicalTrials.gov. A study evaluating the impact of regular FODMAP-targeting digestive enzyme blend use on gastrointestinal symptoms in individuals with self-reported bloating. NCT07591584
Tuck CJ, Taylor KM, Gibson PR, Barrett JS, Muir JG. Increasing symptoms in irritable bowel symptoms with ingestion of galacto-oligosaccharides are mitigated by α-galactosidase treatment. American Journal of Gastroenterology. 2018;113(1):124–134. doi:10.1038/ajg.2017.245
Böhn L, Törnblom H, Van Oudenhove L, Simrén M, Störsrud S. A randomized double-blind placebo-controlled crossover pilot study: acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome patients. Neurogastroenterology and Motility. 2021;33(7):e14094. doi:10.1111/nmo.14094
Hillilä M, Färkkilä MA, Sipponen T, Rajala J, Koskenpato J. Does oral α-galactosidase relieve irritable bowel symptoms? Scandinavian Journal of Gastroenterology. 2016;51(1):16–21. doi:10.3109/00365521.2015.1063156
Komericki P, Akkilic-Materna M, Strimitzer T, et al. Oral xylose isomerase decreases breath hydrogen excretion and improves gastrointestinal symptoms in fructose malabsorption – a double-blind, placebo-controlled study. Alimentary Pharmacology & Therapeutics. 2012;36(10):980–987. doi:10.1111/apt.12057
Yang X, Shui X. Characteristics and clinical applicability of four dietary interventions for irritable bowel syndrome: a systematic review and meta-analysis. Clinical Nutrition. 2026;62:106680. doi:10.1016/j.clnu.2026.106680
Pham VT, Steinert RE, Duysburgh C, et al. In vitro effect of enzymes and human milk oligosaccharides on FODMAP digestion and fecal microbiota composition. Nutrients. 2023;15(7):1637. doi:10.3390/nu15071637
General information only, not individual medical advice. Always discuss supplements and herbal medicines with your treating practitioner.
Adrian StoneGeelong Mon–Wed, Sat
Drysdale Thu
Initial consultation 60 min · $189
Follow-ups 30 min · $89 · No referral needed
Initial consultation 60 min · $189 · Follow-ups 30 min · $89 · No referral needed
Initial consultations are prepaid, whether in clinic, by telehealth or by phone.
For private health consultation claiming, please enquire with your health fund to assess coverage. Nutrition consultations are covered by some private health funds — please check with yours first.
Or call (03) 5201 0557
Probiotics and MS: What a New Trial Says About Fatigue (and What It Can’t)
Alpha Lipoic Acid and Progressive MS: What the OCTOPUS Trial’s Early Results Really Mean
Perimenopause Anxiety: Why It Happens and What Actually Helps